Evidence map›Paper›PMID 35682635›Full record

ArticleInternational journal of molecular sciences2022

Antiproliferative Effects of the Aptamer d(GGGT)

Antonella Virgilio, Annalisa Pecoraro, Daniela Benigno, Annapina Russo, Giulia Russo, Veronica Esposito, Aldo Galeone

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Antonella VirgilioDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, Italy.ORCID 0000-0002-0873-5250
Annalisa PecoraroDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, Italy.
Daniela BenignoDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, Italy.ORCID 0000-0002-5371-1813
Annapina RussoDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, Italy.ORCID 0000-0002-7509-3702
Giulia RussoDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, Italy.ORCID 0000-0003-3891-3350
Veronica EspositoDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, Italy.ORCID 0000-0002-1724-7128
Aldo GaleoneDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, Italy.ORCID 0000-0001-8805-6348
University of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, we study the T30923 antiproliferative potential and the contribution of its loop residues in six different human cancer cell lines by preparing five T30923 variants using the single residue replacement approach of loop thymidine with an abasic site mimic (S). G-rich oligonucleotides (GRO) show interesting anticancer properties because of their capability to adopt G-quadruplex structures (G4s), such as the G4 HIV-1 integrase inhibitor T30923. Considering the multi-targeted effects of G4-aptamers and the limited number of cancer cell lines tested, particularly for T30923, it should be important to find a suitable tumor line, in addition to considering that the effects also strictly depend on G4s. CD, NMR and non-denaturating polyacrylamide gel electrophoresis data clearly show that all modified ODNs closely resemble the dimeric structure of parallel G4s' parent aptamer, keeping the resistance in biological environments substantially unchanged, as shown by nuclease stability assay. The antiproliferative effects of T30923 and its variants are tried in vitro by MTT assays, showing interesting cytotoxic activity, depending on time and dose, for all G4s, especially in MDA-MB-231 cells with a reduction in cell viability approximately up to 30%. Among all derivatives, QS12 results are the most promising, showing more pronounced cytotoxic effects both in MDA-MB-231 and Hela cells, with a decrease in cell viability from 70% to 60%. In summary, the single loop residue S substitution approach may be useful for designing antiproliferative G4s, considering that most of them, characterized by single residue loops, may be able to bind different targets in several cancer cell pathways. Generally, this approach could be of benefit by revealing some minimal functional structures, stimulating further studies aimed at the development of novel anticancer drugs.

Indexed as

Antineoplastic AgentsAptamers, NucleotideG-QuadruplexesHIV Integrase InhibitorsNeoplasmsHeLa CellsHumansThymidineAntineoplastic AgentsAptamers, NucleotideHIV Integrase InhibitorsThymidineabasic site mimicantiproliferative G-quadruplexcancerguanine-rich oligonucleotides

Identifiers

PMID35682635
PMCPMC9181107
OpenAlexW4281552572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.